The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Presented positive topline data from the pivotal Phase 2b ReNeu trial evaluating mirdametinib, an investigational oral MEK inhibitor, in pediatric and adult patients with neurofibromatosis type ...
SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...
STAMFORD, Conn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today ...
Despite the recent approval of SpringWorks Therapeutics’ Ogsiveo, GSK is calling it quits on prior plans to wed the Pfizer spinout’s drug with its withdrawn cancer med Blenrep. SpringWorks on Thursday ...
Hosted on MSN
SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout
Shares of SpringWorks Therapeutics Inc. ended over 9% higher on Thursday following a report that the company is inching closer to getting acquired by an established giant, triggering a jump in ...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
FDA approved SpringWorks' mirdametinib for NF1 patients with symptomatic plexiform neurofibromas, granting a priority review voucher. In the Phase 2b trial, Gomekli showed a 41% ORR in adults and 52% ...
NEW YORK--(BUSINESS WIRE)--SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its ...
– Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and ...
SpringWorks Therapeutics, Inc. SWTX expanded its existing clinical collaboration agreement with GSK GSK. The partnership is evaluating the combination of SpringWorks’ investigational oral gamma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results